Abstracts tagged "spondyloarthritis"

Abstract Number: 1405 • ACR Convergence 2023
Diagnostic Delay of Axial Spondyloarthritis in African American Patients
John Byun¹, Hans Vitzthum von Eckstaedt¹, Kichul Ko² and Reem Jan¹, ¹University of Chicago, Chicago, IL, ²The University of Chicago, Chicago, IL
Background/Purpose: The identification of axial spondyloarthritis (axSpA) remains challenging. The initial presentation is not always immediately apparent as an inflammatory disease, potentially leading to years…
Abstract Number: 1790 • ACR Convergence 2023
Expansion of CD8+ TCRVβ9+ T Cells in the Peripheral Blood of HLA-B27+ Patients with Axial Spondyloarthritis
Caroline Bauchiero¹, Micah Lefton¹, Stephanie Sinnappan², Jeffrey Sparks³ and Joerg Ermann⁴, ¹Brigham and Women's Hospital, Boston, MA, ²Columbia University, New York, NY, ³Division of Rheumatology, Inflammation, and Immunity, Brigham and Women’s Hospital and Harvard Medical School, Boston, MA, ⁴Division of Rheumatology, Inflammation and Immunity, Brigham and Women's Hospital and Harvard Medical School, Boston, MA
Background/Purpose: Studies in human HLA-B27 transgenic rats largely discredited the idea that CD8+ T cells are key drivers of disease in axial spondyloarthritis (axSpA). However,…
Abstract Number: 2196 • ACR Convergence 2023
Females with Axial Spondyloarthritis Report Higher Burden of Disease and Worse Patient-reported Outcomes. Results from the International Map of Axial Spondyloarthritis (IMAS)
Victoria Navarro-Compán¹, Marco Garrido-Cumbrera², Denis Poddubnyy³, Christine Bundy⁴, Souzi Makri⁵, Jose Correa Fernandez⁶, Shashank Murlidhar Akerkar⁷, Lillann Wermskog⁸, Elie Karam⁹, Asif Siddiqui¹⁰ and Fernando Sommerfleck¹¹, ¹Department of Rheumatology, La Paz University Hospital, IdiPaz, Madrid, Spain, ²University of Seville, Sevilla, Spain, ³Department of Gastroenterology, Infectious Diseases and Rheumatology, Charité – Universitätsmedizin Berlin, Berlin, Germany, ⁴Cardiff University, Cardiff, United Kingdom, ⁵Cyprus League for People with Rheumatism (CYLPER), Nicosia, Cyprus, ⁶Universidad de Sevilla, Health & Territory Research (HTR), Sevilla, Spain, ⁷Mumbai Arthritis Clinic, Mumbai, India, ⁸Spondyloarthritis Association of Norwary (SPAFO);Axial Spondyloarthritis International Federation (ASIF), Oslo, Norway, ⁹Canadian Spondylitis Association (CSA), Toronto, ON, Canada, ¹⁰Novartis Pharma AG, Basel, Switzerland, ¹¹Sanatorio Julio Mendez, Buenos Aires, Argentina
Background/Purpose: There is increasing evidence of differences between males and females in axial spondyloarthritis (axSpA), but the source is restricted to specific geographic locations or…
Abstract Number: 2214 • ACR Convergence 2023
Systematic Literature Review and Meta-analysis Informing the Development of 2023 Spondyloarthritis Research and Treatment Network (SPARTAN) Referral Recommendations for Axial Spondyloarthritis
Abhijeet Danve¹, Maureen Dubreuil², Swetha Ann Alexander³, Yuliya afinogenova⁴, Mohamad Bittar⁵, Alyssa Grimshaw⁶, Liana Fraenkel⁷, Michael LaValley⁸, Anand Kumthekar⁹, Jean liew¹⁰, Marina Nighat Magrey¹¹, Vikas Majithia¹², Sali Merjanah¹³, Hillary Norton¹⁴, Jessica A Walsh¹⁵ and Atul Deodhar¹⁶, ¹Yale University School of Medicine, Glastonbury, CT, ²Department of Rheumatology, Boston University School of Medicine, Milton, MA, ³University of Utah Health, Salt Lake City, UT, ⁴Yale, Hamden, CT, ⁵The University of Tennessee Health Science Center, Memphis, TN, ⁶Yale University, New Haven, CT, ⁷Berkshire Health Systems, Lenox, MA, ⁸Boston University School of Public Health, Arlington, MA, ⁹Montefiore Medical Center/Albert Einstein College of Medicine, Bronx, NY, ¹⁰Boston University, Boston, MA, ¹¹Case Western Reserve University, University Hospitals, Cleveland, OH, ¹²Mayo Clinic Florida, Jacksonville, FL, ¹³Boston University Chobanian & Avedisian School of Medicine, Boston, MA, ¹⁴Inspire Santa Fe Rheumatology, Santa Fe, NM, ¹⁵Salt Lake City Veterans Affairs Health and University of Utah Health, Division of Rheumatology, Salt Lake City, UT, ¹⁶Division of Arthritis and Rheumatic Disease, Oregon Health & Science University, Portland, OR
Background/Purpose: Lack of timely referral of suspected axSpA patients to rheumatologists contributes to misdiagnosis, delayed treatment, and poor outcomes. Currently there are no formal guidelines…
Abstract Number: 2547 • ACR Convergence 2023
Characteristics of Difficult-To-Treat Axial Spondyloarthritis: Results of a Multicentric Retrospective Study
Cecile PHILIPPOTEAUX¹, Thibaut DELEPINE², Emeline Cailliau¹, Peggy Philippe¹, Nicolas TAISNE³, Tristan Pascart⁴, Julien Paccou¹, Bernard Cortet¹, Rene-Marc Flipo¹ and Jean-Guillaume Letarouilly⁵, ¹University Hospital Center of Lille, Lille, France, ²CHU de Lille, Lille University Hospital, Valenciennes, France, ³Valenciennes Hospital Center, Valenciennes, France, ⁴Department of Rheumatology, Saint-Philibert Hospital, Lille Catholic University, Lille, France, ⁵CHU Lille, Lille, France
Background/Purpose: The EULAR task force recently published the difficult-to-treat (D2T) RA definition1, however, a definition of D2T axSpA is still lacking. To date, we have…
Abstract Number: 0075 • ACR Convergence 2023
Proteomic, Transcriptomic, and T-Cell Receptor (TCR) Profiling of Synovial Integrin-Expressing (InEx) T Cells in Axial Spondyloarthritis (axSpA)
Zoya Qaiyum¹, Michael Tang² and Robert Inman², ¹Krembil Research Institute, Toronto, ON, Canada, ²University Health Network, Toronto, ON, Canada
Background/Purpose: The strong clinical and genetic associations between axial spondyloarthritis (axSpA) and inflammatory bowel disease (IBD) underscore the pathogenic role of the gut-joint axis. The…
Abstract Number: 0510 • ACR Convergence 2023
Bimekizumab Treatment Improved Key Patient-Reported Symptoms of Axial Spondyloarthritis Including Spinal Pain, Fatigue, and Morning Stiffness: 52-Week Results from Two Phase 3 Studies
Philip J. Mease¹, Maxime Dougados², Maureen Dubreuil³, Marina Nighat Magrey⁴, Helena Marzo-Ortega⁵, Martin Rudwaleit⁶, Christine de la Loge⁷, Carmen Fleurinck⁸, Ute Massow⁹, Vanessa Taieb¹⁰ and Atul Deodhar¹¹, ¹Swedish Medical Center/Providence St. Joseph Health and University of Washington School of Medicine, Seattle, WA, ²Department of Rheumatology, Hôpital Cochin, University of Paris Cité, Paris, France, ³Department of Rheumatology, Boston University School of Medicine, Milton, MA, ⁴Case Western Reserve University, University Hospitals, Cleveland, OH, ⁵NIHR Leeds Biomedical Research Centre, Leeds Teaching Hospitals NHS Trust and Leeds Institute of Rheumatic and Musculoskeletal Medicine, University of Leeds, Leeds, United Kingdom, ⁶University of Bielefeld, Klinikum Bielefeld, Bielefeld, Germany, ⁷UCB Pharma, Brussels, Belgium, ⁸UCB Pharma, Oosterzele, Belgium, ⁹UCB Pharma, Monheim am Rhein, Germany, ¹⁰UCB Pharma, Colombes, France, ¹¹Division of Arthritis and Rheumatic Disease, Oregon Health & Science University, Portland, OR
Background/Purpose: Bimekizumab (BKZ) is a monoclonal IgG1 antibody that selectively inhibits IL-17F in addition to IL-17A. In the phase 3 studies BE MOBILE 1 and…
Abstract Number: 0538 • ACR Convergence 2023
The Challenge of Identifying Difficult-To-Treat Axial Spondyloarthritis in Clinical Practice: Results from La Paz-SpA Cohort
Manuel Juárez¹, Diego Benavent², Victoria Navarro-Compán³, Mariana Díaz-Almirón⁴, Marta Novella-Navarro⁵, Diana Peiteado¹, Alejandro Villalba¹, Irene Monjo⁶, Laura Nuño⁷, Alejandro Balsa⁵ and Chamaida Plasencia-Rodríguez⁵, ¹Rheumatology Department, La Paz University Hospital, Madrid, Spain, ²Hospital la Paz, Madrid, Spain, ³Department of Rheumatology, La Paz University Hospital, IdiPaz, Madrid, Spain, ⁴Biostatistics Unit, IdiPAZ, La Paz University Hospital, Madrid, Spain, ⁵Hospital Universitario La Paz, Madrid, Spain, ⁶University Hospital La Paz, Madrid, Spain, ⁷Hospital Universitario La Paz - IdiPAZ, Madrid, Spain
Background/Purpose: Despite multiple pharmacological options for axSpA are available, still one out of three patients do not achieve the recommended treatment target (1), highlighting the…
Abstract Number: 1081 • ACR Convergence 2023
Clinical Consequences of Infliximab Immunogenicity and the Impact of Proactive Therapeutic Drug Monitoring: Secondary Analyses of a Randomised Clinical Trial
Marthe Brun¹, Kristin Hammersbøen Bjørlykke², Johanna E. Gehin³, David John Warren³, Rolf A. Klaasen³, Joseph Sexton¹, Øystein Sandanger⁴, Tore Kvien¹, Cato Mørk⁵, Jørgen Jahnsen², Nils Bolstad³, Kristin Kaasen Jørgensen², Espen Haavardsholm¹, Guro Goll¹ and Silje Watterdal Syversen¹, ¹Center for Treatment of Rheumatic and Musculoskeletal Diseases (REMEDY), Diakonhjemmet Hospital, Oslo, Norway, ²Department of Gastroenterology, Akershus University Hospital, Oslo, Norway, ³Dept. of Medical Biochemistry, Oslo University Hospital, Oslo, Norway, ⁴Section of Dermatology, Oslo University Hospital, Oslo, Norway, ⁵Akershus Dermatology Center, Lørenskog, Norway
Background/Purpose: Formation of anti-drug antibodies (ADAb) to biological drugs is a clinical problem. Proactive therapeutic drug monitoring (TDM) allows for timely detection of ADAb and…
Abstract Number: 1406 • ACR Convergence 2023
Temporal Trends in Cardiovascular Events in Axial Spondyloarthritis Patients with Medicare Insurance versus Commercial Insurance: An Analysis Using Claims Data
Rouhin Sen¹, Justin Leach¹, Maria I. ("Maio") Danila², Fenglong Xie¹, Jasvinder Singh¹, Liron Caplan³, Iris Navarro-Millán⁴ and Jeffrey Curtis¹, ¹University of Alabama at Birmingham, Birmingham, AL, ²University of Alabama at Birmingham (UAB), Birmingham VA Medical Center, Birmingham, AL, ³Rocky Mountain Regional VAMC, Aurora, CO, ⁴Weill Cornell Medicine, Hospital for Special Surgery, New York, NY
Background/Purpose: AS is an inflammatory disorder of the axial skeleton and can cause complications including disabling joint damage. Nearly 20% of people with AS are…
Abstract Number: 1793 • ACR Convergence 2023
Goblet Cell Specific Anti-Apoptotic Role of Interleukin-24 in Spondyloarthritis-Associated Ileitis
Amy Cameron¹, Rabina Giri², Jakob Begun², Timothy Wells¹, Ranjeny Thomas³ and Anne-Sophie Bergot¹, ¹Frazer Institute, The University of Queensland, Woolloongabba, Australia, ²Mater Research Institute-UQ, Woolloongabba, Australia, ³Frazer Institute, The University of Queensland, Brisbane, Australia
Background/Purpose: The loss of intestinal barrier integrity is a key contributor to gut inflammation, however the mechanism behind this dysregulation is not well understood. The…
Abstract Number: 2197 • ACR Convergence 2023
Diagnostic Delay in Patients Included in the International Map of Axial Spondyloarthrtis: Associations with Geographic, Socio-demographic and Disease-related Factors
Denis Poddubnyy¹, Marco Garrido-Cumbrera², Fernando Sommerfleck³, Victoria Navarro-Compán⁴, Christine Bundy⁵, Souzi Makri⁶, Jose Correa Fernandez⁷, Shashank Murlidhar Akerkar⁸, Jo Davies⁹, Laura Christen¹⁰ and Elie Karam¹¹, ¹Department of Gastroenterology, Infectious Diseases and Rheumatology, Charité – Universitätsmedizin Berlin, Berlin, Germany, ²University of Seville, Sevilla, Spain, ³Sanatorio Julio Mendez, Buenos Aires, Argentina, ⁴Department of Rheumatology, La Paz University Hospital, IdiPaz, Madrid, Spain, ⁵Cardiff University, Cardiff, United Kingdom, ⁶Cyprus League for People with Rheumatism (CYLPER), Nicosia, Cyprus, ⁷Universidad de Sevilla, Health & Territory Research (HTR), Sevilla, Spain, ⁸Mumbai Arthritis Clinic, Mumbai, India, ⁹Axial Spondyloarthritis International Federation (ASIF), London, United Kingdom, ¹⁰Novartis Pharma AG, Basel, Switzerland, ¹¹Canadian Spondylitis Association (CSA), Toronto, ON, Canada
Background/Purpose: Despite efforts for early detection, delayed diagnosis in axial spondyloarthritis (axSpA) remains an unresolved challenge. This analysis aimed to assess diagnostic delay and its…
Abstract Number: 2215 • ACR Convergence 2023
Can Axial Spondyloarthritis Unequivocally Be Diagnosed by Rheumatologists in Patients with Chronic Back Pain of Less Than Two Years Duration? The Primary Outcome of the Two-year SPondyloArthritis Caught Early (SPACE) Cohort
Mary Lucy marques¹, Sofia Ramiro², Miranda Van Lunteren³, Rosalinde Stal³, Robert BM Landewé⁴, Marleen van de Sande⁵, Karen Minde Fagerli⁶, Inger Jorid Berg⁶, Maikel van oosterhout⁷, Sofia Exarchou⁸, Roberta Ramonda⁹, Désirée van der Heijde² and Floris Van Gaalen³, ¹Leiden University Medical Center; Centro Hospitalar e Universitário de Coimbra (Department of Rheumatology), Coimbra, Portugal, ²Department of Rheumatology, Leiden University Medical Center, Leiden, Netherlands, ³Leiden University Medical Center, Department of Rheumatology, Leiden, Netherlands, ⁴Amsterdam Rheumatology & Clinical Immunology Center, Amsterdam and Zuyderland MC, Herleen, Netherlands, ⁵Amsterdam UMC, University of Amsterdam, Department of Rheumatology & Clinical Immunology and Department of Experimental Immunology, Amsterdam Infection & Immunity Institute; Amsterdam Rheumatology & Immunology Center (ARC), Academic Medical Center, Amsterdam, Netherlands, ⁶Center for Treatment of Rheumatic and Musculoskeletal Diseases (REMEDY), Diakonhjemmet Hospital, Oslo, Norway, ⁷Groene Hart Ziekenhuis, Gouda, Netherlands, ⁸Lund University, Åkarp, Sweden, ⁹University of Padova, Department of Rheumatology, Padova, Italy
Background/Purpose: Unacceptable diagnostic delay in axial Spondyloarthritis (axSpA) remains an issue. In 2008, the longitudinal SPondyloArthritis Caught Early (SPACE)-cohort started to assess the prevalence of…
Abstract Number: 2548 • ACR Convergence 2023
Low Uveitis Rates in Patients with Axial Spondyloarthritis Treated with Bimekizumab: Pooled Results from Phase 2b/3 Trials
Martin Rudwaleit¹, Matthew A. Brown², Floris Van Gaalen³, Nigil Haroon⁴, Lianne Gensler⁵, Carmen Fleurinck⁶, Alexander Marten⁷, Ute Massow⁸, Natasha De Peyrecave⁹, Thomas Vaux¹⁰, Katy White¹⁰, Atul Deodhar¹¹ and Irene van der Horst-Bruinsma¹², ¹University of Bielefeld, Klinikum Bielefeld, Bielefeld, Germany, ²Genomics England, London, United Kingdom, ³Leiden University Medical Center, Department of Rheumatology, Leiden, Netherlands, ⁴University of Toronto, University Health Network, Schroeder Arthritis Institute, Department of Medicine/Rheumatology, Toronto, ON, Canada, ⁵University of California San Francisco, Department of Medicine, Division of Rheumatology, San Francisco, CA, ⁶UCB Pharma, Oosterzele, Belgium, ⁷UCB Pharma, Monheim, Germany, ⁸UCB Pharma, Monheim am Rhein, Germany, ⁹UCB Pharma, Brussels, Belgium, ¹⁰UCB Pharma, Slough, United Kingdom, ¹¹Division of Arthritis and Rheumatic Disease, Oregon Health & Science University, Portland, OR, ¹²Radboud University Medical Centre, Department of Rheumatology, Nijmegen, Netherlands
Background/Purpose: Acute anterior uveitis ('uveitis'), or 'iritis', is a common extra-musculoskeletal manifestation among patients (pts) with axial spondyloarthritis (axSpA).1 IL-17 has been implicated in the…
Abstract Number: 0092 • ACR Convergence 2023
Multi-omics Immune Profiling of Cytotoxic T Cells from Ankylosing Spondylitis Patients Identified a Subset of Clonally Exapnded CTLs That Evade Immune Exhaustion
Michael Tang¹, Zoya Qaiyum², Melissa Lim¹ and Robert Inman¹, ¹University Health Network, Toronto, ON, Canada, ²Krembil Research Institute, Toronto, ON, Canada
Background/Purpose: Sustained chronic inflammation in the spine and of the sacroiliac joints is a key feature in Ankylosing Spondylitis (AS). A central role of CTL…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].